期刊文献+

善宁对大鼠肝部分切除术后种植性肝癌作用的实验研究 被引量:6

Effects of octreotide on implanted liver tumor after partial hepatectomy in rats
原文传递
导出
摘要 目的 探讨生长抑素类似物善宁对肝部分切除术后种植性肝癌的作用及其相关机制。 方法 以Wistar大鼠种植性肝癌模型为研究对象 ,将 6 4只雄性Wistar大鼠随机分为 4组 ,每组 16只。A组行单纯右肝叶肿瘤种植 ,B、C、D组均行左肝叶切除加右肝叶肿瘤种植。C、D组分别为术后12h、72h开始首次善宁治疗组 (5 0ug/kg,腹腔内注射 ,每日 2次 )。A、B组为对照组 (生理盐水 ,方法与剂量同上 )。 结果 术后 1周 ,A组肿瘤体积明显小于B、C、D组 (P <0 0 1)。C、D组的肿瘤体积明显小于B组 (P <0 0 1) ,而肿瘤细胞的凋亡率则明显高于B组 (P <0 0 1)。C组与D组的肿瘤体积和细胞凋亡率之间亦存在显著差异 (P <0 0 1)。 结论 善宁可以抑制术后肝肿瘤的生长。 Objectives To investigate the effects of octreotide(OCT) on experimental live tumor after partial hepatectomy (PH) in rats and explore its intrinsic mechanism. Methods Sixty-four male rats were randomly divided into four groups and operated on with laparotomy. Walker-256 tumor was implanted in all the four groups. Group A served as the control, and groups B, C and D received left lobe PH. Octreotide at a dose of 50 μg/kg was intraperitoneally(IP)administered twice a day in groups C and D (OCT). The time of the first administration was at the 12th hour after PH in group C and the 72nd hour after PH in group D. The rats in groups A and B received a similar volume of normal saline (NS). Results Group A showed a significant reduction of implanted liver tumor volume at the 7th day versus group B (P<0.01). Groups C and D showed a significant reduction of tumor volume at the 7th and 15th day versus group B(P<0.01). The tumor cell apoptotic rate was significantly higher in groups C and D than in groups A and B at the 7th and 15th day(P<0.01). Conclusion The growth of experimental liver tumor is enhanced after PH bat can be inhibited by OCT.
出处 《中华外科杂志》 CAS CSCD 北大核心 2001年第12期948-950,共3页 Chinese Journal of Surgery
关键词 奥曲肽 肝细胞癌 肝切除术 脱噬作用 善宁 大鼠 Octreotide Carcinoma, hepatocellular Hepatectomy Apoptosis
  • 相关文献

参考文献1

二级参考文献2

  • 1钱振超,中华肿瘤杂志,1987年,9卷,187页
  • 2周金煦,中华肿瘤杂志,1986年,8卷,409页

共引文献42

同被引文献37

  • 1Patel YC,Srikant CB.Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors(hsstr1-5)[J].Endocrinology,1994,135(6):2814-2817.
  • 2Fiebiger WC,Scheithauer W,Traub T,et al.Absence of therapeutic efficacy of the somatostatin analogue lanreotide in advanced primary hepatic cholangiocellular cancer and adenocarcinoma of the gallbladder despite in vivo somatostatin-receptor expression[J].Scand J Gastroenterol,2002,37:222-225.
  • 3Dimitroulopoulos D,Xinopoulos D,Tsamakidis K,et al.The role of sandostatin LAR in treating patients with advanced hepatocellular cancer[J].Hepatogastroenterology,2002,49:1245-1250.
  • 4Kouroumalis E,Skordilis P,Thermos K,et al.Treatment of hepatocellular carcinoma with octreotide:a randomised controlled study[J].Gut,1998,42:442-447.
  • 5Eden PA,Taylor JE.Somatostatin receptor subtype gene expression in human and rodent tumors[J].Life Sci,1993,53: 85-90.
  • 6Reubi JC,Zimmermann A,Jonas S,et al.Regulatory peptide receptors in human hepatocellular carcinomas[J].Gut,1999,45:766-774.
  • 7Bruno JF,Xu Y.Tissue distribution of somatostatin receptor subtype messenger robonucleic acid in the rat[J].Endocrinology,1993,33:2561-2567.
  • 8Theveniau MA,Yasuda K,Bell GI,et al.Immunological detection of isomorfs of the somatostatin receptor Subtype,SSTR2[J].F Neruochem,1994,63:447-455.
  • 9Burghardt B,Barabas K,Marcsek Z,et al.Inhibitory effect of a long-acting somatostatin analogue on EGF-stimulated cell proliferation in Capan-2 cells[J].J Physiol Paris,2000,94: 57-62.
  • 10Chen X,Liu Z,Ai Z.Antineoplastic mechanism of Oc-treotide action in human hepatoma[J].Chin Med J(Engl),2001,114(11): 1167-1170.

引证文献6

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部